Passage Bio (Passage Bio) EBIT per Share : $-1.55 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Passage Bio EBIT per Share?

Passage Bio's EBIT per Share for the three months ended in Mar. 2024 was $-0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.55.

During the past 3 years, the average EBIT per Share Growth Rate was 13.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -35.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Passage Bio's EBIT per Share or its related term are showing as below:

PASG' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -99.3 Med: -38.8 Max: 13.4
Current: 13.4

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Passage Bio was 13.40% per year. The lowest was -99.30% per year. And the median was -38.80% per year.

PASG's 3-Year EBIT Growth Rate is ranked better than
63.49% of 1301 companies
in the Biotechnology industry
Industry Median: 3.4 vs PASG: 13.40

Passage Bio's EBIT for the three months ended in Mar. 2024 was $-18.05 Mil.

Passage Bio EBIT per Share Historical Data

The historical data trend for Passage Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Passage Bio EBIT per Share Chart

Passage Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.93

-2.90

-3.33

-2.49

-1.88

Passage Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.66	-0.46	-0.43	-0.34	-0.32

Passage Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Passage Bio's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-102.999	/	54.743
=	-1.88

Passage Bio's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-18.05	/	56.296
=	-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.55

Passage Bio (NAS:PASG) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Passage Bio EBIT per Share Related Terms

Thank you for viewing the detailed overview of Passage Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Passage Bio (Passage Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Passage Bio Inc (NAS:PASG) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103

Website

https://www.passagebio.com

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Executives

Kathleen Borthwick	officer: SVP, Interim CFO	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Simona King	officer: Chief Financial Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Dolan Sondhi	director	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alexandros Fotopoulos	officer: Chief Technical Officer	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Sandip Kapadia	director	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
William Chou	director, officer: Chief Executive Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Monika Maria Toernsen	officer: Chief Commercial Officer	ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Michael E. Kamarck	director	C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Mark S Forman	officer: Chief Medical Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Bruce A Goldsmith	director, officer: CEO and President	C/O PASSAGE BIO, INC., TWO COMMERCE SQ, 2001 MARKET ST, 28TH FL, PHILADELPHIA PA 19103
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Brian Burkavage	officer: Controller	C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Derrell Porter	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341